Substrate-specific modulation of CYP3A4 activity by genetic variants of cytochrome P450 oxidoreductase
- 1 October 2010
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Pharmacogenetics and Genomics
- Vol. 20 (10), 611-618
- https://doi.org/10.1097/fpc.0b013e32833e0cb5
Abstract
Objectives CYP3A4 receives electrons from P450 oxidoreductase (POR) to metabolize about 50% of clinically used drugs. There is substantial inter-individual variation in CYP3A4 catalytic activity that is not explained by CYP3A4 genetic variants. CYP3A4 is flexible and distensible, permitting it to accommodate substrates varying in shape and size. To elucidate the mechanisms of variability in CYP3A4 catalysis, we examined the effects of genetic variants of POR, and explored the possibility that substrate-induced conformational changes in CYP3A4 differentially affect the ability of POR variants to support catalysis. Methods We expressed human CYP3A4 and four POR variants (Q153R, A287P, R457H, A503 V) in bacteria, reconstituted them in vitro and measured the Michaelis constant and maximum velocity with testosterone, midazolam, quinidine and erythromycin as substrates. Results POR A287P and R457H had low activity with all substrates; Q153R had 76–94% of wild-type (WT) activity with midazolam and erythromycin, but 129–150% activity with testosterone and quinidine. The A503 V polymorphism reduced the CYP3A4 activity to 61–77% of WT with testosterone and midazolam, but had nearly WT activity with quinidine and erythromycin. Conclusion POR variants affect CYP3A4 activities. The impact of a POR variant on catalysis by CYP3A4 is substrate-specific, probably because of substrate-induced conformational changes in CYP3A4.Keywords
This publication has 53 references indexed in Scilit:
- Clinical, Genetic, and Enzymatic Characterization of P450 Oxidoreductase Deficiency in Four PatientsJournal of Clinical Endocrinology & Metabolism, 2009
- Domain Motion in Cytochrome P450 ReductasePublished by Elsevier BV ,2009
- Human Cytochrome P450 Oxidoreductase Deficiency Caused by the Y181D Mutation: Molecular Consequences and Rescue of DefectDrug Metabolism and Disposition, 2009
- Polymorphism of Human Cytochrome P450 2D6 and Its Clinical SignificanceClinical Pharmacokinetics, 2009
- Nomenclature for alleles of the cytochrome P450 oxidoreductase genePharmacogenetics and Genomics, 2009
- The Common P450 Oxidoreductase Variant A503V Is Not a Modifier Gene for 21-Hydroxylase DeficiencyJournal of Clinical Endocrinology & Metabolism, 2008
- Genetics of P450 oxidoreductase: Sequence variation in 842 individuals of four ethnicities and activities of 15 missense mutationsProceedings of the National Academy of Sciences of the United States of America, 2008
- Identifying genetic risk factors for serious adverse drug reactions: current progress and challengesNature Reviews Drug Discovery, 2007
- Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin actionJCI Insight, 2007
- Structural basis for ligand promiscuity in cytochrome P450 3A4Proceedings of the National Academy of Sciences of the United States of America, 2006